tiprankstipranks
Advertisement
Advertisement

Karyopharm sees 2026 revenue $130M-$150M, consensus $146.86M

Expects its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into Q2.

Claim 55% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1